Cure My Disease

Don't miss your cure!

 Log in / Sign up

Triple PET imaging could sharpen epilepsy surgery targeting

NCT ID NCT07147309

Diagnosis Sponsor: Weibing Miao, PhD Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study tests whether combining three different PET scans can more accurately pinpoint the brain area causing seizures in people with drug-resistant epilepsy. The three tracers measure glucose metabolism, synaptic density, and inflammation, each highlighting different features of epileptic tissue. Participants will undergo all three scans before surgery, and researchers will compare the imaging results with surgical outcomes to see which combination best guides removal of the seizure focus.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
three PET tracers: 18F-FDG, SV2A, and TSPO
What this could lead to
If successful, this approach could improve surgical outcomes for drug-resistant epilepsy by more precisely identifying the brain tissue that needs to be removed.
What could go wrong
This is a small, early-stage imaging study, not a treatment trial. The tracers may not improve surgical planning enough to change outcomes, and the results may not apply to all epilepsy types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with drug-resistant focal epilepsy.

Ages

18 to 50 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * with drug-resistant focal epilepsy defined by ILAE criteria * Already performed 3.0 T epilepsy-protocol MRI and video-EEG * Planned resective surgery or stereotactic EEG (SEEG) electrode implantation, and willingness to undergo all three PET scans: ¹⁸F-FDG, SV2A, and TSPO. * Ability to understand study procedures and provide written informed consent. * Availability of complete postoperative follow-up data with at least 12-month Engel outcome classification. Exclusion Criteria: -History of head trauma ,claustrophobia, rheumatic or autoimmune diseases, psychiatric disorders, severe somatic diseases (neurological,cardiovascular, etc.),previous heart or brain surgery, substance abuse, inability to refrain from hypnotics, magnetic implants, pregnancy, lactation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Epilepsy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Epilepsy FDG pet Microglial activation Pet / MR Synaptic vesicle proteins

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The First Affiliated Hospital of Fujian Medical University

    RECRUITING

    Fuzhou, Fujian, 350005, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.